U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22O8
Molecular Weight 414.4053
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PODOFILOX

SMILES

[H][C@]12COC(=O)[C@]1([H])[C@H](C3=CC(OC)=C(OC)C(OC)=C3)C4=C(C=C5OCOC5=C4)[C@@H]2O

InChI

InChIKey=YJGVMLPVUAXIQN-XVVDYKMHSA-N
InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1

HIDE SMILES / InChI
Molecular Formula C22H22O8
Molecular Weight 414.4053
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/?term=9562603 http://products.sanofi.ca/en/condyline.pdf

Podofilox ((abbreviated as PPT), otherwise known as podofilox) is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Podofilox 0.5% solution is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts. Treatment of genital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown, but is believed to exert its antimitotic effect by binding to tubulin, at a site close to but not identical to the binding site of colchicine; it is thought that this antimitotic effect causes necrosis of wart tissue, the observed clinical effect. In addition, podofilox is known to interfere with nucleoside transport, which may also contribute to its action. Adverse effects reported in less than 5% of the patients included pain with intercourse, insomnia, tingling, bleeding, tenderness, chafing, malodor, dizziness, scarring, vesicle formation, crusting edema, dryness/peeling, foreskin irretraction, hematuria, vomiting and ulceration.

Approval Year

1990
108
Targets

Targets

Primary TargetPharmacologyConditionPotency
Tubulin
69
Target ID: CHEMBL2095182
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
CONDYLOX

Approved Use

Podofilox Topical Solution 0.5% is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts (see PRECAUTIONS ). Diagnosis Although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma (so-called Bowenoid papulosis) is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with Podofilox Topical Solution 0.5%.

Launch Date

1990
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
17 ng/mL
DRUG LABEL
https://www.drugs.com/pro/podofilox.html
1.5 mL single, topical
dose: 1.5 mL
route of administration: Topical
experiment type: SINGLE
co-administered:
PODOFILOX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.5 h
DRUG LABEL
https://www.drugs.com/pro/podofilox.html
1.5 mL single, topical
dose: 1.5 mL
route of administration: Topical
experiment type: SINGLE
co-administered:
PODOFILOX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (79.2%)
Pain (79.2%)
Itching (83.3%)
Bleeding (45.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (49.4%)
Pain (54.3%)
Itching (59.3%)
Bleeding (29.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (52.3%)
Pain (55.8%)
Itching (60.5%)
Bleeding (32.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (83.2%)
Pain (49.6%)
Itching (52.9%)
Bleeding (28.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (81.9%)
Pain (50.4%)
Itching (52.8%)
Bleeding (26.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (71.4%)
Pain (71.4%)
Itching (57.1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Other AEs: Inflammation, Pain...
Other AEs:
Inflammation (mild, 32.2%)
Pain (mild, 23.7%)
Itching (mild, 32.2%)
Bleeding (mild, 19.2%)
Inflammation (moderate, 30.4%)
Pain (moderate, 20.4%)
Itching (moderate, 16%)
Bleeding (moderate, 3%)
Inflammation (severe, 9.3%)
Pain (severe, 11.5%)
Itching (severe, 7.8%)
Bleeding (severe, 0.7%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Bleeding 45.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 79.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 79.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 83.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 26
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: F
Population Size: 26
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Bleeding 29.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 49.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 54.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 59.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 82
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: F
Population Size: 82
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Bleeding 32.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 52.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 55.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 60.5%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 86
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: F
Population Size: 86
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Bleeding 28.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 49.6%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 52.9%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 83.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 119
Health Status: unhealthy
Condition: External genital warts
Age Group: adult
Sex: M
Population Size: 119
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Bleeding 26.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 50.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 52.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 81.9%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 127
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sex: M
Population Size: 127
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Itching 57.1%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Inflammation 71.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Pain 71.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
unhealthy, adult
n = 14
Health Status: unhealthy
Condition: Perianal warts
Age Group: adult
Sex: M
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/9449907/
Bleeding mild, 19.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Pain mild, 23.7%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Inflammation mild, 32.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Itching mild, 32.2%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Itching moderate, 16%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Pain moderate, 20.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Bleeding moderate, 3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Inflammation moderate, 30.4%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Bleeding severe, 0.7%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Pain severe, 11.5%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Itching severe, 7.8%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Inflammation severe, 9.3%
0.5 % 2 times / day multiple, topical
Recommended
Dose: 0.5 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.5 %, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
unhealthy, adult
Health Status: unhealthy
Condition: Anogenital warts
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/1997/020529s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587
inhibitor
1767
inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
UGT1A1
204

CYP2C8
911

CYP2E1
882

CYP2A6
707
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2A6
739
 no
CYP2C8
965
 no
CYP2D6
1891
 no
CYP2E1
970
 no
CYP3A4
1925
 yes [IC50 1.1 uM]
CYP2C9
1819
 yes [IC50 4.6 uM]
MRP1
172
 yes
P-gp
1650
 yes
UGT1A1
254
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-0462
http://www.3bsc.com/index/pro_info.php?id=19818
3B Scientific (Wuhan) Corp
3B1-00688
http://www.3bsc.com/index/pro_info.php?id=20900
AA Blocks
AA003A9R
https://www.aablocks.com/goods/Goods/detail?id=AA003A9R
AHH Chemical co.,ltd
API-1441
http://www.ahhchemical.com/product/API-1441.html
AHH Chemical co.,ltd
MT-58075
http://www.ahhchemical.com/product/MT-58075.html
AHH Chemical co.,ltd
NP-0421
http://www.ahhchemical.com/product/NP-0421.html
AK Scientific, Inc. (AKSCI)
70719
http://www.aksci.com/item_detail.php?cat=70719
Aaron Chemicals
AR003B1J
http://www.aaronchem.com/518-28-5
AbMole Bioscience
M3496
http://www.abmole.com/products/podophyllotoxin.html
Achemtek
0104-003876
http://www.achemtek.com/518-28-5
Acorn PharmaTech
ACN-035836
http://www.acornpharmatech.com/
Acros Organics
AC228411000
https://www.fishersci.com/shop/products/podophyllotoxin-95-acros-organics-1/AC228411000
Acros Organics
AC228410010
https://www.fishersci.com/shop/products/podophyllotoxin-95-acros-organics/AC228410010
Alfa Chemistry
125670-69-1
https://www.alfa-chemistry.com/cas_125670-69-1.htm
Alinda
ALBB-020906
http://alinda.ru/finechem_en_.html?i=ALBB-020906
Aurum Pharmatech LLC
W-5067
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5067
AvaChem Scientific
2680
http://www.avachem.com/productSearch.asp?2680
Axon MedChem
3368
https://www.axonmedchem.com/product/3368
BLD Pharm
BD41750
http://www.bldpharm.com/products/518-28-5.html
BioChemPartner
BCP24085
http://www.biochempartner.com/518-28-5-BCP24085
BioSynth
P-6980
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/P-6980.html
Boerchem
BC202956
http://www.boerchem.com/?product_34100.html
CSNpharm
CSN16748
https://www.csnpharm.com/products/podophyllotoxin.html
Capot Chemical
20017
http://www.capotchem.com/en/20017.htm
Capot Chemical
PubChem20017
http://www.capotchem.com/en/20017.htm
Chem Scene
CS-1185
http://www.chemscene.com/518-28-5.html
ChemFaces
CFN99168
http://www.chemfaces.com/natural/Podophyllotoxin-CFN99168.html
ChemMol
30101274
http://www.chemmol.com/chemmol/30101274.html
ChemMol
44001388
http://www.chemmol.com/chemmol/44001388.html
ChemMol
99098085
http://www.chemmol.com/chemmol/99098085.html
Chemenu
CM110307
http://www.chemenu.com/products/CM110307
Chemspace
CSSB00000743982
https://chem-space.com/CSSB00000743982
Clearsynth
CS-O-30735
https://www.clearsynth.com/en/CSO30735.html
DAOGE BIOPHARMA
DG21-11821
https://www.daogechem.com/product/518-28-5.html
DC Chemicals
DCG-007
http://www.dcchemicals.com//product_show-Podophyllotoxin.html
Glentham Life Sciences
GE0412
http://www.glentham.com/products/product/GE0412/
Hairui
HR138842
http://www.hairuichem.com/en/product/518-28-5.html
Herbest Bio-Tech
HP200546
http://www.bjherbest.com/analytical-standard/lignans/podophyllotoxin-518-28-5.html
Lab Network
LN00178261
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00178261
Matrix Scientific
79670
https://www.matrixscientific.com/079670.html
MedChem Express
HY-15552
https://www.medchemexpress.com/Podophyllotoxin.html
MuseChem
I003874
https://www.musechem.com/product/I003874.html
OChem
12425
http://www.ocheminc.com/index.php?act=psearch&pid=518P285
Oakwood
358381
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=162982&ExtHyperLink=1
Otava
12486930
https://search.otavachemicals.com/#!/search?query=12486930&type=code&base=dbb
Parchem
36299
http://www.parchem.com/chemical-supplier-distributor/podophyllotoxin-026299.aspx
R&D Chemicals
8646
http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=8165
Renno Tech
RL03911
http://www.rennotech.com/product_show.asp?id=4231
Sigma-Aldrich
858447_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/858447?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
73379_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/73379?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
P4405_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/p4405?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
TripleBond
CP0089
http://www.triplebond-canada.com/prod/1520/
VladaChem
VL262072-100MG
https://www.vladachem.com/product.php?products=518-28-5
Yuhao Chemical
JZ2488
http://www.chemyuhao.com/4354-76-1.html
abcr GmbH
AB167899
http://www.abcr.com/shop/en/AB167899
eNovation Chemicals
D512514
https://www.enovationchem.com/ProductDetails.asp?ProductID=D512514
iChemical
EBD2184800
http://www.ichemical.com/products/518-28-5.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule
MCULE-9617461427
https://mcule.com/MCULE-9617461427/
PubMed

PubMed

TitleDatePubMed
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Prevention and management of antineoplastic-induced hypersensitivity reactions.
2001
Imiquimod for the treatment of genital warts: a quantitative systematic review.
2001
Issues and practicalities of treating genital warts in the community. Proceedings of a round table meeting facilitated by Succinct Communications Limited.
2001
Antitumor agents. Synthesis and biological evaluation of new compounds related to podophyllotoxin, containing the 2,3-dihydro-1,4-benzodioxin system.
2001 Apr
Condyloma eradication: self-therapy with 0.15-0.5% podophyllotoxin versus 20-25% podophyllin preparations--an integrated safety assessment.
2001 Apr
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
2001 Apr
Secoisolariciresinol dehydrogenase purification, cloning, and functional expression. Implications for human health protection.
2001 Apr 20
Factors involved in clearance of genital warts.
2001 Dec
A fast and simple GC MS method for lignan profiling in Anthriscus sylvestris and biosynthetically related Plant species.
2001 Dec
[Synthesis and activities of 4-deoxy-4 beta-arylmehtylene sulfonylamido-4'-demethylpodophyllotoxins].
2001 Feb
Podophyllotoxin lignans enhance IL-1beta but suppress TNF-alpha mRNA expression in LPS-treated monocytes.
2001 Feb
High yield of podophyllotoxin from leaves of Podophyllum peltatum by in situ conversion of podophyllotoxin 4- O-beta-D-glucopyranoside.
2001 Feb
[Clinical aspects and therapy of anogenital warts and papillomavirus-associated lesions].
2001 Jan
[PAPP-A in the first trimester of pregnancy].
2001 Jul
A novel topoisomerase II poison GL331 preferentially induces DNA cleavage at (C/G)T sites and can cause telomere DNA damage.
2001 Jun
The production of cytotoxic lignans by plant cell cultures.
2001 Mar
Contact dermatitis from topical antiviral drugs.
2001 May
Analytical approaches for traditional chinese medicines exhibiting antineoplastic activity.
2001 Nov 25
Management of anogenital warts (condylomata acuminata).
2001 Nov-Dec
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
2001 Oct
Advances in cancer therapy with plant based natural products.
2001 Oct
Silencer activity of NFATc2 in the interleukin-12 receptor beta 2 proximal promoter in human T helper cells.
2001 Sep 14
Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia.
2002
[High-dose chemotherapy with autologous bone marrow transplantation in children with high-risk malignant neoformations].
2002
Evaluation of Podophyllum peltatum accessions for podophyllotoxin production.
2002 Apr
Biological activity of 4-acetyltropolone, the minor component of Thujopsis dolabrata SIeb. et Zucc. hondai Mak.
2002 Aug
An epiisopicropodophyllin aza analogue via palladium-catalyzed pseudo-domino cyclization.
2002 Dec 27
Treatment of non-Hodgkin's lymphoma in the elderly. The Italian studies.
2002 Jan-Feb
Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells.
2002 Jul-Aug
Optimization of culture parameters for production of podophyllotoxin in suspension culture of Podophyllum hexandrum.
2002 Jul-Dec
A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
2002 Jun 25
Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex.
2002 Mar 14
Effect of the DNA topoisomerase II inhibitor VP-16 on illegitimate recombination in yeast chromosomes.
2002 May 29
Zinc enhances the expression of interleukin-2 and interleukin-2 receptors in HUT-78 cells by way of NF-kappaB activation.
2002 Oct
Experimental study of podophyllotoxin dipalmitoylphosphatidylcholine liposome for topical skin application.
2002 Oct
Biosynthesis of podophyllotoxin in Linum album cell cultures.
2002 Oct
Methamphetamine activates DNA binding of specific redox-responsive transcription factors in mouse brain.
2002 Oct 1
Meiotic telomere clustering is inhibited by colchicine but does not require cytoplasmic microtubules.
2002 Oct 1
External genital warts: diagnosis, treatment, and prevention.
2002 Oct 15
A multicomponent reaction for the one-pot synthesis of 4-aza-2,3-didehydropodophyllotoxin and derivatives.
2002 Sep 19
Transcription factor IID recruitment and Sp1 activation. Dual function of TAF1 in cyclin D1 transcription.
2003 Apr 11
Naphthalene analogues of lignans.
2003 Feb 7
Synthesis and cytotoxicity of podophyllotoxin analogues modified in the A ring.
2003 Jan
Effect of major nutrients on podophyllotoxin production in Podophyllum hexandrum suspension cultures.
2003 Jan
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
2003 Jan
Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.
2003 Jan 13
[Bacteremia due to Capnocytophaga spp.: two cases].
2003 Mar
Patents

Patents

05463040
2
JP2002541233A
400
JP2007508039A
114
JP2009526755A
447
JP4701159B2
70
JP4758474B2
87
JPH03262488A
1
JPH0753553A
2
JPH08269041A
1
JPS62294609A
1

Sample Use Guides

In Vivo Use Guide
Apply twice daily morning and evening (every 12 hours), for 3 consecutive days, then withhold use for 4 consecutive days. This 1 week cycle of treatment may be repeated up to four times until there is no visible wart tissue. Podofilox 0.5% solution is applied to the warts with a cotton-tipped applicator supplied with the drug. The drug-dampened applicator should be touched to the wart to be treated, applying the minimum amount of solution necessary to cover the lesion. Treatment should be limited to less than 10 cm2 of wart tissue and to no more than 0.5 mL of the solution per day.
Route of Administration: Vaginal
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:18:02 GMT 2023
Edited
by admin
on Fri Dec 15 15:18:02 GMT 2023
Record UNII
L36H50F353
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PODOFILOX
HSDB   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
PODOPHYLLOTOXIN [EP MONOGRAPH]
Common Name English
NSC-24818
Code English
PODOFILOX [VANDF]
Common Name English
Podophyllotoxin
MART.   MI   WHO-DD  
Common Name English
PODOFILOX [ORANGE BOOK]
Common Name English
Podophyllotoxin [WHO-DD]
Common Name English
PODOPHYLLOTOXIN [MI]
Common Name English
PODOPHYLLOTOXIN [MART.]
Common Name English
CONDYLOX
Brand Name English
PODOFILOX [HSDB]
Common Name English
FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE, 5,8,8A,9-TETRAHYDRO-9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-, (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.ALPHA.))-
Common Name English
(5R,5AR,8AR,9R)-5,8,8A,9-TETRAHYDRO-9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE
Common Name English
PODOFILOX [USAN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000008732
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
NCI_THESAURUS C67421
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
WHO-ATC D06BB04
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
WHO-VATC QD06BB04
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
Code System Code Type Description
PUBCHEM
10607
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
HSDB
7238
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
EVMPD
SUB14925MIG
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
RXCUI
8463
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m8933
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL61
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
NSC
24818
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
CAS
518-28-5
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
FDA UNII
L36H50F353
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
NCI_THESAURUS
C29368
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
WIKIPEDIA
PODOPHYLLOTOXIN
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
DRUG CENTRAL
3481
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
SMS_ID
100000091097
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
CHEBI
50305
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
MESH
D011034
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
USAN
AA-10
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
ECHA (EC/EINECS)
208-250-4
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID3045645
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
DRUG BANK
DB01179
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
DAILYMED
L36H50F353
Created by admin on Fri Dec 15 15:18:02 GMT 2023 , Edited by admin on Fri Dec 15 15:18:02 GMT 2023
PRIMARY
Related Record Type Details
TUBULIN BETA CHAIN
TARGET -> INHIBITOR
Related Record Type Details
Structure of PICROPODOPHYLLIN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of PODOFILOX
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966